16 November 2026

CEO blog: London Life Sciences Week; bioProcessUK get underway alongside early-stage sector fundraising

Headshot of Chris Molloy, CEO of BIA

Chris Molloy
CEO, BIA

Dear colleagues,

Greetings from the thick of London Life Sciences Week, which got underway yesterday with a packed Welcome Reception hosted by BIA, MedCity and London & Partners. London is hosting thousands of investors and international visitors to what is now an established stop on the global life sciences trail.

It now has over 100 fringe events across all disciplines and with significant Government support. Across all these events we shall demonstrate the best of the UK’s offering to a global audience.

BIA’s International Investor Summit will welcome over 150 global investors to our ecosytem to build new links with our expert VC community and member companies. We will bring together institutions, Science Minister Chris McDonald and British Business Bank to agree tangible objectives for greater flows of private funding.

We have talked a lot about making this money move. I want this week’s decisions to lead to actions, with a time-bounded focus on delivering the start-up and scale-up money that businesses need to thrive.

Wednesday and Thursday our bioProcessUK conference convenes the UK biomanufacturing community in Brighton. I am looking forward to spending time with the people building this sovereign capability which turns scientific progress into medicines. If you are joining us, use the partnering sessions to start a practical conversation about what you can do together.

There is also fresh investment to welcome. BIA member Oyster Therapeutics has closed a £45 million Series A-2 round to advance its work on targeted protein degraders for treatment of Alzheimer’s. This adds to the already strong start to Q4, with raises from BIA members OMass, imphatec and Microbiotica to name a few.

In this update:

London Life Sciences Week: connecting UK biotech with global investors

Sunday’s Welcome to London Reception marked the official launch, hosted by us in partnership with MedCity and London & Partners. The invitation-only event brought international investors and biotech leaders into the same room. That is where useful connections begin; the follow-up is where we turn them into something tangible

I spoke at Cell & Gene Leaders Live which brought ATMP leaders together at The Shard to discuss the future of advanced therapies. Hosted by Onyx with support from BIA, Act for Hope and One Nucleus, it put a winning area of UK life sciences firmly in focus.

The £22 million announcement for three projects from London mayor Sadiq Khan this morning is great news to kick off this year’s London Life Sciences Week.

Flagship Pioneering also announced an initial £100 million to launch an AI-focused company creation lab in London, its first outside the US, with about 50 scientists and operators to be recruited in the UK. It hopes to attract a further £500 million through partnership.

This morning I spoke at the Crick Institute – on their 10th anniversary – about the importance of teamwork on translation. Later today at Canada House I shall promote building better bio-bridges with international partners lined by free trade and regulatory agreements, such as the Access Consortium. I will pick up this discussion on Tuesday’s panel at the global regulatory (DIA-MHRA) conference. This is a global team effort, performed with chosen partners. To cement these relationships, we welcome international delegations at a new breakfast for 2027

On Wednesday, I am looking forward to our discussion with Science Minister Chris McDonald at the International Investor Summit. Hosted by BIA in collaboration with UK Government, the summit brings global investors together with BIA member companies to explore high-growth investment opportunities.

Our job remains to help investors and international partners to see the opportunity in UK biotech and for our policymakers to give companies the right economic environment to make medicines.

bioProcessUK Brighton: build UK biomanufacturing partnerships

bioProcessUK kicks off tomorrow in Brighton, and there is still time to secure a last-minute ticket. I am looking forward to getting together with the UK’s biomanufacturing community. This is where we strengthen the relationships that help our sector deliver. Thank you to Merck for being the Host Supporter of the conference.

This year we are happy to announce our innovation lounge. For the first time, attendees can enjoy the space’s posters, innovation showcase companies, barista coffee, 1-1 partnering and sofa breakout zones.

Adam Wilkinson of Microbiotica will be speaking, following the company’s £36 million Series C last month. He will share the stage with Annelise Soulier of Neobe Therapeutics, which has just closed a £5.1 million seed round, and with speakers from GutSee Health and CPI. Two UK companies and two fundraises on one panel is a good reason to be in the room.

The three-day gathering includes pre-conference networking followed by a two-day conference. High-profile speakers, from Cath Green, Head of Clinical BioManufacturing Facility, University of Oxford, to Jonathan Haigh, Senior Vice President, Head of UK Site at FUJIFILM Biotechnologies, will share the latest bioprocessing developments, while the exhibition gives delegates a chance to explore innovation across the sector. Industry awards and student poster sessions are part of the programme, with interactive voting giving attendees a direct role.

Come ready to talk about what your business needs and where you can help others. As with every bioProcessUK I want us to leave Brighton with new relationships we can build on and clear next steps for sector success.

Oyster Therapeutics raises £45 million for targeting novel modality for Alzheimer’s

BIA member Oyster Therapeutics (previously known as Kesmalea Therapeutics) has closed a £45 million Series A-2 financing round. The company is targeting a novel modality for Alzheimer’s. The strong funding start to Q4 continues.

The round was led by London-based early-stage specialist life sciences investor 4BIO Capital. New investors included Eli Lilly and Company, CE Ventures, Actium Group and TOHO Ventures, managed by Global Brain. Existing investors Syncona, Oxford Science Enterprises, Mission BioCapital and MGB Ventures also participated.

This is welcome early-stage backing for a BIA member pursuing a significant commercial opportunity. As we meet investors during London Life Sciences Week, Oyster’s financing gives us a concrete example of capital coming together behind UK biotech.

Wherever you are in the UK this week, know that the world is watching…